User:Mr. Ibrahem/Idarubicin

Mr. Ibrahem/Idarubicin
Clinical data
Pronunciation	/ˌaɪdəˈruːbɪsɪn/
Trade names	Zavedos, Idamycin, others
Other names	Idarubicin hydrochloride, 4-demethoxydaunorubicin, 9-acetyl-7-(4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-6,9,11-trihydroxy-7,8,9,10-tetrahydrotetracene-5,12-dione
AHFS/Drugs.com	Monograph
MedlinePlus	a691004
Drug class	Anthracycline
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Protein binding	97%
Elimination half-life	22 hours
Identifiers
	IUPAC name (1S,3S)-3-acetyl-3,5,12-trihydroxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxo-α-L-lyxo-hexopyranoside;
Chemical and physical data
Formula	C26H27NO9
Molar mass	497.500 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2c1c(O)c5c(c(O)c1C(=O)c3ccccc23)C[C@@](O)(C(=O)C)C[C@@H]5O[C@@H]4O[C@H]([C@@H](O)[C@@H](N)C4)C;
	InChI InChI=1S/C26H27NO9/c1-10-21(29)15(27)7-17(35-10)36-16-9-26(34,11(2)28)8-14-18(16)25(33)20-19(24(14)32)22(30)12-5-3-4-6-13(12)23(20)31/h3-6,10,15-17,21,29,32-34H,7-9,27H2,1-2H3/t10-,15-,16-,17-,21+,26-/m0/s1 ; Key:XDXDZDZNSLXDNA-TZNDIEGXSA-N ;
	(verify)

Idarubicin, sold under the brand name Zavedos and Idamycin, is a medication used to treat acute myeloid leukemia (AML) and breast cancer.^[2]^[3] It is often used with cytarabine.^[2] It is given by injection into a vein or taken by mouth.^[2]^[3]

Common side effects include nausea, hair loss, abdominal pain, diarrhea, bleeding, mouth inflammation, fever, and headache.^[2] Other side effects may include heart failure, arrhythmias, bone marrow suppression, high uric acid, liver problems, kidney problems.^[2] Use in pregnancy may harm the baby.^[2] It is an anthracycline and acts similar to daunorubicin.^[1]

Idarubicin was approved for medical use in the United States in 1990.^[2] In the United Kingdom 10 mg for injection costs the NHS about £175 as of 2021.^[3] In the United States this amount costs about 70 USD.^[4]

References[edit]

^ ^a ^b "Doxorubicin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 May 2021. Retrieved 25 November 2021.
^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "IDArubicin Monograph for Professionals". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.
^ ^a ^b ^c ^d BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 948. ISBN 978-0857114105.
^ "Idarubicin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.

[Liv2021-1] "Doxorubicin". LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. National Institute of Diabetes and Digestive and Kidney Diseases. 2012. Archived from the original on 16 May 2021. Retrieved 25 November 2021.

[AHFS2021-2] ^ ^a ^b ^c ^d ^e ^f ^g ^h ⁱ "IDArubicin Monograph for Professionals". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.

[BNF81-3] BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 948. ISBN 978-0857114105.

[4] "Idarubicin Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 23 May 2021. Retrieved 25 November 2021.

[1]

[2]

[3]

[4]